Close Menu

NEW YORK (GenomeWeb) — Adaptive Biotechnologies intends to offer 12.5 million shares of its common stock at between $15 and $17 apiece in its planned initial public offering, the immunosequencing firm said in a filing with the US Securities and Exchange Commission on Monday.

If the shares float at the top end of the expected range, Adaptive will raise $212.5 million through the IPO. If the underwriters of the IPO exercise their option to buy an additional 1.875 million shares, Adaptive could raise up to $244.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.